Flying Brands Limited IB announce agreement to develop a diagnostic tool (0651C)
September 27 2018 - 1:00AM
UK Regulatory
TIDMFBDU
RNS Number : 0651C
Flying Brands Limited
27 September 2018
Flying Brands Limited
("Flying Brands" or the "Company")
Imaging Biometrics announce agreement to develop a diagnostic
tool for liver surface nodularity.
Imaging Biometrics(R), LLC ("IB"), a subsidiary of Flying Brands
Limited (LON:FBDU), announces today that it has been awarded a
development contract by the Board of Trustees of the University of
Alabama ("UAB") to develop a product to quantify liver surface
nodularity ("LSN") - a biomarker derived from routine computed
tomographic ("CT") images, which allows prediction of cirrhosis
decompensation and death. UAB will pay IB a fee to develop the
software plus an additional fee for regulatory services.
In a paper published in "Radiology" in November 2016, the
study's authors concluded that the LSN score derived from routine
CT images allows prediction of cirrhosis decompensation and death.
IB is seeking to translate these findings into a commercially
robust software product that will streamline this process, and that
will quickly and efficiently determine how well patients are
responding to treatment. The agreement also includes preparing and
submitting an application to the US FDA for obtaining regulatory
market clearance.
Imaging Biometrics' CEO, David Smith said, "We believe this
agreement could generate significant revenues for Imaging
Biometrics. UAB's decision to enlist Imaging Biometrics as a
development partner underscores their confidence in Imaging
Biometrics' proven track record of commercialising advanced imaging
technologies into routine clinical applications. We are excited
about this opportunity and look forward to the possibility of
entering into future agreements with UAB."
About Imaging Biometrics
Imaging Biometrics, a subsidiary of Flying Brands Limited
(LON:FBDU), develops and provides visualisation and analytical
solutions that enable clinicians to better diagnose and treat
diseases with greater confidence. Through close collaboration with
top researchers and clinicians, sophisticated advancements are
translated into platform-independent software plug-ins which can
extend the base functionality of workstations, imaging systems,
PACS, or medical viewers. By design, IB's advanced visualisation
software seamlessly integrates into routine workflows. For more
information about Imaging Biometrics, visit the company's website
at www.imagingbiometrics.com.
Flying Brands Limited (Ticker:FBDU) is the parent company of
StoneChecker(R) and Imaging Biometrics(R) focused on advanced and
state of the art medical software and services.
(www.flyingbrands.co.uk).
The Directors of the Company accept responsibility for the
contents of this announcement.
For further information, please contact:
Flying Brands Limited
Qu Li/Trevor Brown/Vinod Kaushal
Tel: 020 7469 0930
----------------------------------------------------------
Peterhouse Capital Limited (Financial Adviser and Broker)
Lucy Williams/Heena Karani
Tel: 020 7220 9797
----------------------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGRKMGZLKVZGRZM
(END) Dow Jones Newswires
September 27, 2018 02:00 ET (06:00 GMT)
Flying Brand (LSE:FBDU)
Historical Stock Chart
From Dec 2024 to Jan 2025
Flying Brand (LSE:FBDU)
Historical Stock Chart
From Jan 2024 to Jan 2025